Clinical trials: AAA
Alzheimer Disease, Dementia
MEMORI Corps: Activity-based Companion Care for Dementia
This project adapts a novel activity-based companion care model, the Making Engagement Meaningful through Organized Routine Interaction (MEMORI) Corps intervention, for a virtual delivery format, and then implements the…
- Trial name
- MEMORI Corps (NCT03896711)
- Testing
- MEMORI Corps program, Augmented Waitlist Control
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
OSA, Sleep Apnea
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
Obstructive sleep apnea (OSA) is common in older adults and has recently been implicated in pathogenesis of Alzheimer's disease (AD). Research has shown that sleep disruptions have caused memory impairment.
- Conditions
- OSA, Sleep Apnea, Obstructive Sleep Apnea, Alzheimer Disease
- Trial name
- NCT05094271
- Testing
- Supplemental Oxygen, Continuous Positive Airway Pressure Machine, Room Air
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of California, San Diego
Alzheimer Disease
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive performance and global function in patients with…
- Trial name
- Combi (NCT00911807)
- Testing
- Cerebrolysin + donepezil
- Where
- 3 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Ever Neuro Pharma GmbH
Abdominal Aortic Aneurysm
GORE® EXCLUDER® Endoprosthesis French Mandatory Registry
This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® Excluder® Endoprosthesis in the treatment of infra-renal Abdominal Aortic Aneurysms (AAA).
- Trial name
- NCT02308839
- Testing
- GORE® EXCLUDER® Endoprosthesis
- Where
- France
- Volunteers
- 181 people
- Sponsor
- W.L.Gore & Associates
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Alzheimer Disease
Tau Screening Study in Subjects With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03467477
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 9 sites in United States
- Volunteers
- 161 people
- Sponsor
- Avid Radiopharmaceuticals
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease, Seizures
Seizure Activity in Alzheimer's Disease
The main purpose of this research project is to study how seizure-like activity affects the blood flow in the brain of patients with Alzheimer's disease (AD).
- Trial name
- NCT01554683
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Beth Israel Deaconess Medical Center
Dementia, Alzheimer Type
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
A recent study (Saltmarche et al., 21017) examined the effects of photobiomodulation (PBM), a kind of light therapy that uses red or near-infrared light to heal and protect tissue that has either been injured, is degenerating, or…
- Trial name
- PBM Dementia (NCT03160027)
- Testing
- Vielight Neuro Gamma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959.
- Trial name
- NCT02560753
- Testing
- T3D-959
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Senile Dementia, Alzheimer Type
A Study of Mobile Medical Supportive Care Program for Family Caregivers With Dementia Combined With Diabetes
The purpose of this project is to evaluate the effectiveness of the clinical application of a mHealth supportive care program for family caregivers with dementia combined with diabetes based on the supportive care framework.
- Trial name
- NCT06785857
- Testing
- mHealth Supportive Care Program, Offline supportive care
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuanjiao Yan
Alzheimer Disease, Mild to Moderate Alzheimer Disease
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT03520998
- Testing
- GRF6019
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkahest, Inc.
Alzheimer Disease
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.
- Trial name
- NCT01181921
- Testing
- Galantamine
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag, S.A.
Abdominal Aortic Aneurysm Without Rupture
EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study
Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.
- Trial name
- EVAS2 (NCT03298477)
- Testing
- Nellix® System
- Where
- 27 sites in United States
- Volunteers
- 98 people
- Sponsor
- Endologix
Alzheimer's Disease
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the…
- Trial name
- THC-AD (NCT02792257)
- Testing
- Dronabinol (Marinol®)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johns Hopkins University
Alzheimer Dementia (AD)
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
- Trial name
- NCT02553928
- Testing
- Memantine (once daily), Memantine (twice daily)
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease
Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Patients with Alzheimer's disease (AD) can have seizures in addition to losing their memory and other mental functions (referred to as cognitive functions).
- Trial name
- LEV-AD (NCT02002819)
- Testing
- levetiracetam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Minnesota
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Brain Health, Gestational Hypertension
Brain Health in Midlife
The purpose of this study is to learn if hypertensive disorders during pregnancy affects brain health in midlife.
- Conditions
- Brain Health, Gestational Hypertension, Alzheimer Disease, Dementia
- Trial name
- ADORE BRAIN (NCT06640842)
- Testing
- A combination of various tests and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy on brain health in midlife.
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center